PhoreMost and Plexxikon collaborate to identify novel drug targets
16-Apr-2018 -
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.
Under the agreement, PhoreMost will apply its ...
collaborations
Daiichi Sankyo
drug discovery collaborations
+1